Prevnar News and Research RSS Feed - Prevnar News and Research

Medical advisory panel recommends new pneumonia vaccine for seniors

Medical advisory panel recommends new pneumonia vaccine for seniors

The experts expressed concern, however, that Medicare rules may hamper some people from getting the new vaccine if they have already had an older version. Also in drug issues, some patient advocates report that insurers are balking at paying for a costly drug to treat hepatitis C if the patients are in drug treatment programs. [More]
Prevalence of bacterial meningitis drops in the United States

Prevalence of bacterial meningitis drops in the United States

Advances in the prevention and treatment of an often fatal condition called bacterial meningitis appear to be paying dividends in the United States, report infectious disease experts at The University of Texas Health Science Center at Houston (UTHealth) in the journal The Lancet Infectious Diseases. [More]
Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. [More]
Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action. [More]
European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease. [More]
Infant vaccination against pneumonia helps protect elderly

Infant vaccination against pneumonia helps protect elderly

Children who receive a vaccine to prevent blood and ear infections, appear to be reducing the spread of pneumonia to the rest of the population, especially their grandparents and other older adults. [More]
Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae). [More]
Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age. [More]
Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV). [More]
FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine. [More]
EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

Pfizer Inc. announced today that the European Commission has approved expanding the use of the company's pneumococcal conjugate vaccine, Prevenar 13(pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae. [More]
NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases. [More]
Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis. [More]
Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age. [More]
Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years. [More]
Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older. [More]
Pfizer’s Prevenar 13 gets US approval for adults

Pfizer’s Prevenar 13 gets US approval for adults

Health authorities of United States have approved the expansion of Pfizer Inc's Prevnar vaccine for use in adults 50 and older to fight pneumonia, meningitis and other diseases cause by pneumococcus bacteria. The vaccine, which had been approved for children in the United States, is already one of Pfizer's biggest brands and an expanded population of adults could generate more than $1.5 billion in annual sales. [More]
FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae. [More]
FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. [More]
Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer Inc. today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children. [More]